Clinical Trial

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2023-03-14; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2023-05-05
Trial Details
NCT Number NCT05785741
Lead Sponsor DualityBio Inc.
Conditions Advanced Solid Tumor
Enrollment 1,000 participants
Start Date 2023-08-17
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-06